Navigation Links
Clinical Results for Oramed's Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
Date:5/1/2013

s and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-79
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
2. Rush University Medical Center Presents Positive MuGard Clinical Data at the Oncology Nursing Society 38th Annual Congress
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
5. Elekta to Highlight Clinical and Safety Advantages of Gamma Knife Radiosurgery at 2013 AANS Meeting
6. Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
7. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
8. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
9. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
10. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
11. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Critical Process Filtration, ... , today announces the expansion of their Technical ... Process Filtration now offers customers and potential customers ... to filter failure analyses (even for competitor filters) ... their hallmark services of system benchmarking and cost/performance ...
(Date:8/28/2014)... -- Rx Safes, Inc., the manufacturer of fingerprint recognition home ... new war on drugs to reduce prescription drug abuse, ... than 2,500 children a day experiment with prescription drugs ... accessed from unsecured medicine cabinets, closets and drawers.  While law ... Safes will address the new age drug dealer in ...
(Date:8/28/2014)... , Californie, 28 août 2014 ... annoncé aujourd,hui le début des inclusions ... étude  d,exemption des dispositifs expérimentaux (ou ... à évaluer l,innocuité et l,efficacité du ... Le docteur Adam Arthur , ...
Breaking Medicine Technology:Critical Process Filtration, Inc. Announces Expanded Technical Services and Validation Support 2Rx Safes, Inc. Announces New War On Drugs 2Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 2Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 3Sequent Medical annonce le démarrage d'une étude IDE pour le système WEB d'embolisation des anévrismes 4
... 1, 2011 Hologic, Inc. (Hologic or ... developer, manufacturer and supplier of premium diagnostics, medical imaging ... needs of women, today announced it has acquired TCT ... in China, including Hologic,s ThinPrep Pap Test, related instruments ...
... Technology makes the PROFIT 200 list for the third ... Technology, headquartered in Toronto, has been included in the ... by PROFIT Magazine. Ranking Canada,s Fastest-Growing Companies by five-year ... successful growth companies. Published in the Summer issue of ...
Cached Medicine Technology:Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 2Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 3Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 4Hologic Acquires TCT International Co. Ltd., a Leading Distributor of Medical Products in China 5Claron Technology Makes the PROFIT 200 List for the Third Consecutive Year 2
(Date:8/28/2014)... Commercial growers all over the continent are waitlisted ... grow lights, which perform on par with 1000w HPS at ... lighting needs no cooling equipment and does not overheat the ... Factoring in that they never need bulbs changed, the internal ... year. , For many indoor growers, cooler room temperatures also ...
(Date:8/28/2014)... be given to healthy volunteers in the UK, The ... of an series of safety trials of potential vaccines ... than 1,400 people in the current outbreak in West ... co-developed by the US National Institutes of Health (NIH) ... an international consortium in response to the Ebola epidemic, ...
(Date:8/28/2014)... place glue directly on the nerve stumps, but this ... allows glue to easily invade the nerve ends. Ordinarily, ... insert the nerve ends into the conduit because the ... Liang and co-workers from the General Hospital of Chinese ... and defined the best parameters for its use through ...
(Date:8/28/2014)... of patients with stage III colon cancer had improved ... a new study in Gastroenterology ... Association. , When added to the standard chemotherapy treatment ... overall survival rates for patients with the CpG island ... to 20 percent of colorectal cancers. Patients with CIMP-negative ...
(Date:8/28/2014)... in the study who were on a class of ... as prescribed in the first six months. Patients from ... around the UK involved in the study. , Researchers ... Genomics at The University of Manchester, who led the ... known as ,non-adherence, reduced their effectiveness and may lead ...
Breaking Medicine News(10 mins):Health News:New Kind K5 Series LED Grow Lights Pave Way for Future of Indoor Gardening 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:Drug shows promise for subset of stage III colon cancer patients 2Health News:Arthritis patients failing to take expensive medication, according to new research 2
... substantially reduce the risk of ovarian cancer in women ... research. Researchers say the magnitude of the risk reduction ... cancer has the highest fatality rate of all gynecological ... the strong predictors of developing ovarian cancer is a ...
... said on Thursday they were combining two new and experimental ... try to treat muscular dystrophy. Their early work has shown ... is years away. ,Writing in the journal Science, the ... Research Institute in Milan and the University of Rome said ...
... (GH) replacement therapy dosed to normalize IGF-I levels may be ... weight loss program for obese adults. ,The goal of ... retain lean body mass such as muscle,but what happens is ... they stop losing weight. Low levels of GH, known to ...
... rays -- two of which can cause severe skin ... Services at the University of California, the most dangerous ... shorter wavelengths and are primarily responsible for sunburn. Repeated ... immune system and can lead to melanoma and basal ...
... care what the compound microscope was to the biology ... worn on the body, such as a band around ... includes time spent lying down or sleeping, time spent ... ,Few medical advances in recent decades have had ...
... on Friday it expected to announce the removal of the island ... countries where new cases of the deadly virus had been reported ... the disease is 10 days, and twice that time is the ... situation over. ,The move, due to be announced at a ...
Cached Medicine News:Health News:Stem cells offer hope for muscular dystrophy 2Health News:Low-dose Growth Hormone (GH) with diet and exercise may help weight loss 2Health News:SARS-Free Taiwan to Mark End Phase of Global Fight 2
... Single use curved circular ... and titanium staples., ,The ... stapler is used throughout the ... of end-to-end, end-to-side and side-to-side ...
... The Scantibodies Calcitonin Immunoassay is a two-site ... calcitonin. Two different goat polyclonal antibodies to ... chromatography to be specific for well-defined regions ... quantitative determination of Calcitonin in human serum. ...
Calcitonin RIA Kit...
... IMAGE1 is the first completely digital camera ... in the field of endoscopic camera systems. ... the first time, facilitates the fully digital ... quality using an A/D converter, as well ...
Medicine Products: